Oculex Pharmaceuticals

What Oculex Pharmaceuticals does

Oculex Pharmaceuticals, Inc. was a Sunnyvale, California-based drug delivery and pharmaceutical company founded in 1989, focused exclusively on ophthalmic applications. The company specialized in developing drug delivery technology for the treatment of eye diseases and conditions, operating in the use-case segment of ophthalmology and eye care. Its core offering was a proprietary delivery platform designed to administer pharmaceutical agents to the eye, though specific product names, technical architectures, pipeline assets, or approved indications are not documented in the available source data.

The company went through a Series 2 financing of $50,000,000 on 2002-10-22 led by Bay City Capital and Perseus-Soros Biopharmaceutical Fund, with a broader syndicate that included Aisling Capital, Notable Capital, Venture TDF, and Vivo Capital — all specialist healthcare/biopharma investors — providing capital to advance its ophthalmic drug delivery platform. The headcount band of 101–250 employees reflects a mid-stage clinical/pre-commercial organization, though no revenue, pricing model, distribution channel, or product-level commercial metrics are disclosed.

Oculex was acquired by Allergan plc and, following AbbVie's 2020 acquisition of Allergan, became part of AbbVie's broader eye care and pharmaceutical franchise. The original Oculex domain (oculex.com) now redirects to AbbVie content, and no standalone operating entity, management team, or product portfolio remains identifiable — indicating complete operational integration into the parent. As a result, no current independent business model, go-to-market motion, or revenue mechanics can be attributed to Oculex as a standalone company.

Name

Oculex Pharmaceuticals

Legal name

Oculex Pharmaceuticals

Website

https://oculex.com

Company type

Private

Founded year

1989

Operating status

Acquired

Headcount range

101–250 employees

Short description

Oculex Pharmaceuticals was a Sunnyvale, California-based drug delivery and pharmaceutical company founded in 1989 that developed ophthalmic drug delivery technology for treating eye diseases. It was acquired by Allergan, now part of AbbVie, and no longer operates as a standalone entity.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Ophthalmic drug delivery
• Eye care pharmaceuticals
• Ocular therapeutics
• Drug delivery systems
• Ophthalmology treatments

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Core offering

Oculex Pharmaceuticals, Inc. operated as a drug delivery and pharmaceutical company specializing in ophthalmic drug delivery technology. The company developed pharmaceutical treatments and delivery systems for ocular conditions, targeting eye diseases and conditions requiring pharmaceutical intervention. Its technology and intellectual property were subsequently incorporated into Allergan's (now AbbVie's) eye care portfolio.

Product overview

No product or service information available for Oculex Pharmaceuticals in the source data. The domain oculex.com now redirects to AbbVie's website following Allergan's acquisition by AbbVie, and no Oculex-specific product portfolio, technology offerings, or service descriptions were found in the available sources.

Differentiator

Problem solved

Functional benefit

Products and services

• Ophthalmic drug delivery systems

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Alcon: Alcon is a broad incumbent global leader in eye care covering surgical, pharmaceutical, and consumer vision; comparable to Allergan (Oculex's acquirer) as one of the two dominant platforms where ocular drug delivery assets are typically consolidated.
• Allergan (AbbVie): Allergan (now part of AbbVie) is Oculex's direct acquirer and parent company; it is the broad incumbent eye care franchise treating 60+ conditions with 30+ brands, providing the platform through which Oculex's technology reaches patients.
• Bausch + Lomb (Bausch Health): Bausch + Lomb is a broad incumbent in ophthalmology, with a portfolio spanning pharmaceuticals, surgical devices, and consumer vision care; a natural strategic acquirer of ophthalmic specialty pharma peers including ISTA Pharmaceuticals.

Direct peers

• Nicox: Nicox is a European-based specialty ophthalmic pharmaceutical company developing therapeutics for eye diseases; comparable to Oculex as a small-cap specialist focused on ophthalmology indications.
• Ocular Therapeutix: Ocular Therapeutix is a direct peer developing sustained-release drug delivery platforms for ophthalmic applications (including DEXTENZA) using bioabsorbable hydrogel-based inserts; mirrors Oculex's specialty pharma + drug delivery technology approach in retina and anterior segment.
• EyePoint Pharmaceuticals: EyePoint Pharmaceuticals (formerly pSivida) is a direct peer in sustained-release ophthalmic drug delivery, developing bioerodible inserts (DURYSTA, DEXYCU) for the back and front of the eye; it overlaps with Oculex on the core thesis of proprietary ocular implants/drug delivery platforms for eye disease.
• Aerie Pharmaceuticals: Aerie Pharmaceuticals is a direct peer focused on ophthalmic pharmaceuticals for glaucoma and retinal diseases (Rhopressa, Rocklatan), operating in the same specialty ophthalmology commercial category that Oculex targeted.
• ISTA Pharmaceuticals: ISTA Pharmaceuticals was a specialty ophthalmic pharmaceutical company (acquired by Bausch + Lomb in 2012) focused on eye care therapeutics, comparable to Oculex as a similarly-sized specialty ophthalmic pharma with a small-cap, focused commercial model.

Emerging players

• Kala Bio: Kala Bio (formerly Kala Pharmaceuticals) is an emerging ophthalmic specialty pharma developing novel therapies for eye diseases, sharing Oculex's specialty ophthalmology positioning with a focus on inflammation and dry eye indications.
• Graybug Vision: Graybug Vision was an emerging player developing injectable sustained-release ocular drug delivery technologies for wet AMD and glaucoma, intersecting with Oculex's drug-delivery-for-eye-disease thesis but at an earlier stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oculex Pharmaceuticals